Cases
Intermolecular, Inc. (IMI)
Merger
Overview
Overview
- Date:
- 5/6/2019
- Company Name:
- Intermolecular, Inc.
- Stock Symbol:
- IMI
- Company Name - Buyer:
- Merck KGaA, Darmstadt, Germany
- Status:
- Closed/Complete
- Merger Announcement Date:
- 5/6/2019
NEW YORK, May 6, 2019 – Bragar Eagel & Squire, P.C. is investigating potential claims against the board of directors of Intermolecular, Inc. (NYSE: IMI) on behalf of stockholders concerning the proposed acquisition of the company by a wholly owned subsidiary of Merck KGaA, Darmstadt, Germany.
Pursuant to the proposed transaction, announced on May 6, 2019 and valued at $62 million, Intermolecular stockholders will receive $1.20 in cash for each share of Intermolecular common stock owned. The investigation focuses on whether Intermolecular and its board of directors violated the federal securities laws and/or breached their fiduciary duties to the Company’s stockholders by failing to conduct a fair process and whether and by how much the proposed transaction undervalues the Company.
If you own Intermolecular shares, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Melissa Fortunato by email at investigations@bespc.com, or telephone at (212) 308-1869, or by filling out the contact form below. There is no cost or obligation to you.
Pursuant to the proposed transaction, announced on May 6, 2019 and valued at $62 million, Intermolecular stockholders will receive $1.20 in cash for each share of Intermolecular common stock owned. The investigation focuses on whether Intermolecular and its board of directors violated the federal securities laws and/or breached their fiduciary duties to the Company’s stockholders by failing to conduct a fair process and whether and by how much the proposed transaction undervalues the Company.
If you own Intermolecular shares, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Melissa Fortunato by email at investigations@bespc.com, or telephone at (212) 308-1869, or by filling out the contact form below. There is no cost or obligation to you.